Skip to main content
Erschienen in: Tumor Biology 7/2014

01.07.2014 | Research Article

Mir-302 cluster exhibits tumor suppressor properties on human unrestricted somatic stem cells

verfasst von: Fatemeh Jamshidi-Adegani, Lida Langroudi, Abbas Shafiee, Abdollah Mohammadi-Sangcheshmeh, Abdolreza Ardeshirylajimi, Mansoureh Barzegar, Keyhan Azadmanesh, Mahmood Naderi, Ehsan Arefian, Masoud Soleimani

Erschienen in: Tumor Biology | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Many studies have reported that miR-302-367 cluster acts in different ways in various cell types. For instance, this cluster is shown to have a potential role in stemness regulation in embryonic stem cells (ESCs). On the other hand, this cluster inhibits the tumorigenicity of human pluripotent stem cells by coordinated suppression of CDK2 and CDK4/6 cell cycle pathways. Indeed, this cluster has a significant posttranscriptional impact on cell cycle progression. Previous reports have shown the participation of miR-302-367 cluster in cell cycle regulation of hESCs, MCF7, HepG2, and Teta-2 embryonal teratocarcinoma cells, but its effect on unrestricted somatic stem cells (USSCs) as a new source of human somatic stem cells from the umbilical cord blood remains to be elucidated. Therefore, in this study, we aimed to investigate the effect of miR-302-367 cluster on cell proliferation by MTT assay, cell cycle analysis, and colony formation assay. In addition, the expression of candidate cell cycle regulatory performance and tumor suppressor genes was determined. In this study, for the first time, we found that miR-302-367 cluster not only did not reprogram human USSCs into a pluripotent ESC-like state, but also inhibited the proliferation of human USSCs. Moreover, analyzing the cell cycle curve revealed a significant apoptotic phase upon viral introduction of miR-302-367. Our gene expression study revealed the overexpression of candidate genes after transduction of USSCs with miR-302-367 cluster. In conclusion, the controversial role of miR-302-367 in different cell types may provide better understanding for its role in stemness level and its antitumorigenicity potential in different contexts.
Literatur
2.
Zurück zum Zitat Kögler G et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004;200(2):123–35.PubMedCentralCrossRefPubMed Kögler G et al. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J Exp Med. 2004;200(2):123–35.PubMedCentralCrossRefPubMed
3.
Zurück zum Zitat Trompeter H-I et al. MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One. 2011;6(1):e16138.PubMedCentralCrossRefPubMed Trompeter H-I et al. MicroRNAs MiR-17, MiR-20a, and MiR-106b act in concert to modulate E2F activity on cell cycle arrest during neuronal lineage differentiation of USSC. PLoS One. 2011;6(1):e16138.PubMedCentralCrossRefPubMed
4.
Zurück zum Zitat Barroso-del Jesus A, Lucena-Aguilar G, Menendez P. The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle. 2009;8(3):394–8.CrossRefPubMed Barroso-del Jesus A, Lucena-Aguilar G, Menendez P. The miR-302-367 cluster as a potential stemness regulator in ESCs. Cell Cycle. 2009;8(3):394–8.CrossRefPubMed
5.
Zurück zum Zitat Chen D, Farwell MA, Zhang B. MicroRNA as a new player in the cell cycle. J Cell Physiol. 2010;225(2):296–301.CrossRefPubMed Chen D, Farwell MA, Zhang B. MicroRNA as a new player in the cell cycle. J Cell Physiol. 2010;225(2):296–301.CrossRefPubMed
6.
Zurück zum Zitat Johnnidis JB et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451(7182):1125–9.CrossRefPubMed Johnnidis JB et al. Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature. 2008;451(7182):1125–9.CrossRefPubMed
7.
Zurück zum Zitat Kaspi H et al. miR-290-295 regulate embryonic stem cell differentiation propensities by repressing Pax6. Stem Cells. 2013;31(10):2266–72.CrossRefPubMed Kaspi H et al. miR-290-295 regulate embryonic stem cell differentiation propensities by repressing Pax6. Stem Cells. 2013;31(10):2266–72.CrossRefPubMed
8.
Zurück zum Zitat Rahimian A et al. Bypassing the maturation arrest in myeloid cell line U937 by over-expression of microRNA-424. Hematology. 2011;16(5):298–302.CrossRefPubMed Rahimian A et al. Bypassing the maturation arrest in myeloid cell line U937 by over-expression of microRNA-424. Hematology. 2011;16(5):298–302.CrossRefPubMed
9.
Zurück zum Zitat Fallah P, et al. miR-146a and miR-150 promote the differentiation of CD133+ cells into T-lymphoid lineage. Mol Biol Rep. 2013: p. 1–7. Fallah P, et al. miR-146a and miR-150 promote the differentiation of CD133+ cells into T-lymphoid lineage. Mol Biol Rep. 2013: p. 1–7.
10.
Zurück zum Zitat Cai N, Wang Y-D, Zheng P-S. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA. 2013;19(1):85–95.PubMedCentralCrossRefPubMed Cai N, Wang Y-D, Zheng P-S. The microRNA-302-367 cluster suppresses the proliferation of cervical carcinoma cells through the novel target AKT1. RNA. 2013;19(1):85–95.PubMedCentralCrossRefPubMed
12.
Zurück zum Zitat Lin S-L et al. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010;70(22):9473–82.CrossRefPubMed Lin S-L et al. MicroRNA miR-302 inhibits the tumorigenecity of human pluripotent stem cells by coordinate suppression of the CDK2 and CDK4/6 cell cycle pathways. Cancer Res. 2010;70(22):9473–82.CrossRefPubMed
14.
Zurück zum Zitat Kögler G, Sensken S, Wernet P. Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Exp Hematol. 2006;34(11):1589–95.CrossRefPubMed Kögler G, Sensken S, Wernet P. Comparative generation and characterization of pluripotent unrestricted somatic stem cells with mesenchymal stem cells from human cord blood. Exp Hematol. 2006;34(11):1589–95.CrossRefPubMed
15.
Zurück zum Zitat Adegani FJ. et al. A comparison of pluripotency and differentiation status of four mesenchymal adult stem cells. Mol Biol Rep. 2012: p. 1–11. Adegani FJ. et al. A comparison of pluripotency and differentiation status of four mesenchymal adult stem cells. Mol Biol Rep. 2012: p. 1–11.
16.
Zurück zum Zitat Suh M-R et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol. 2004;270(2):488–98.CrossRefPubMed Suh M-R et al. Human embryonic stem cells express a unique set of microRNAs. Dev Biol. 2004;270(2):488–98.CrossRefPubMed
17.
Zurück zum Zitat Kluth SM, Radke TF, Kogler G. Potential application of cord blood-derived stromal cells in cellular therapy and regenerative medicine. J Blood Transfus. 2012. 2012. Kluth SM, Radke TF, Kogler G. Potential application of cord blood-derived stromal cells in cellular therapy and regenerative medicine. J Blood Transfus. 2012. 2012.
18.
Zurück zum Zitat Jalali H et al. Unrestricted somatic stem cells as vehicle for nerve growth factor gene transfer. Neurol Res. 2013;35(6):553–60.CrossRefPubMed Jalali H et al. Unrestricted somatic stem cells as vehicle for nerve growth factor gene transfer. Neurol Res. 2013;35(6):553–60.CrossRefPubMed
19.
Zurück zum Zitat Cho WJ et al. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells. 2009;28(6):521–7.CrossRefPubMed Cho WJ et al. miR-372 regulates cell cycle and apoptosis of ags human gastric cancer cell line through direct regulation of LATS2. Mol Cells. 2009;28(6):521–7.CrossRefPubMed
20.
Zurück zum Zitat Lin, S.-L, Wu DT. Production and utilization of a novel anti-cancer drug in therapy. 2013, US Patent App. 13/964,705. Lin, S.-L, Wu DT. Production and utilization of a novel anti-cancer drug in therapy. 2013, US Patent App. 13/964,705.
21.
Zurück zum Zitat Fareh M et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2011;19(2):232–44.PubMedCentralCrossRefPubMed Fareh M et al. The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network. Cell Death Differ. 2011;19(2):232–44.PubMedCentralCrossRefPubMed
22.
Zurück zum Zitat Wang L et al. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013;13(1):448.PubMedCentralCrossRefPubMed Wang L et al. MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer. 2013;13(1):448.PubMedCentralCrossRefPubMed
Metadaten
Titel
Mir-302 cluster exhibits tumor suppressor properties on human unrestricted somatic stem cells
verfasst von
Fatemeh Jamshidi-Adegani
Lida Langroudi
Abbas Shafiee
Abdollah Mohammadi-Sangcheshmeh
Abdolreza Ardeshirylajimi
Mansoureh Barzegar
Keyhan Azadmanesh
Mahmood Naderi
Ehsan Arefian
Masoud Soleimani
Publikationsdatum
01.07.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 7/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1844-x

Weitere Artikel der Ausgabe 7/2014

Tumor Biology 7/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.